Merck Stock Dips on Mixed Q2 Results Amid Strategic Shift
Merck & Co. shares fell nearly 2% Tuesday, underperforming pharmaceutical peers after reporting a 2% year-over-year revenue decline to $15.8 billion. While cancer drug Keytruda saw 9% sales growth and animal health revenue ROSE 11%, GAAP net income dropped 8% to $5.4 billion.
The results missed revenue estimates but beat adjusted EPS forecasts, prompting CEO Robert Davis to announce a "multi-year optimization initiative" redirecting resources from mature business segments to emerging growth drivers. Market reaction reflects investor skepticism about Merck's transitional phase as it rebalances its portfolio.
Log in to Reply
Log in to comment your thoughtsComments
Related Articles
|Square
Get the BTCC app to start your crypto journey
Get started today Scan to join our 100M+ users